Sarepta Therapeutics Inc
SRPT
Market Cap$12.04B
Close$
$153.22
17.1% upside
Current Fair Value
17.1% upsideUndervalued by 17.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.04 Billion |
|---|---|
| Enterprise Value | $11.60 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-5.8 |
| Beta | 0.0 |
| Outstanding Shares | 94,505,608 |
| Avg 30 Day Volume | 726,299 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -22.46 |
|---|---|
| PEG | 15.84 |
| Price to Sales | 10.07 |
| Price to Book Ratio | 14.54 |
| Enterprise Value to Revenue | 9.33 |
| Enterprise Value to EBIT | -43.32 |
| Enterprise Value to Net Income | -22 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 1.44 |
Revenue Sources
No data
ESG Score
No data
About Sarepta Therapeutics Inc
CEO: Douglas Ingram Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...